Safety and Pharmacokinetic Study of Carbamylated Erythropoietin (CEPO) to Treat Patients With Acute Ischemic Stroke

Inclusion Criteria: * Age between 50 and 90 years * Clinical diagnosis of acute ischemic stroke * Measurable stroke-related deficit * Patient is stable * Treatment can be initiated between 0 hours and 48 hours after the onset of stroke * Expected hospital stay of at least 120 hours after first dose of study medication * If female then not of childbearing potential Exclusion Criteria: * Primary intracerebral haemorrhage (ICH), or parenchymal haemorrhagic transformation of infarction (type PHI or PHII as defined in ECASS), subarachnoid haemorrhage (SAH), arterio-venous malformation (AVM), cerebral aneurysm, or cerebral neoplasm * Treated with a thrombolytic \<24 hours (if \>24 hours and excluded ICH then eligible) * Score \>=1 on the NIHSS item 1a * Pre-stroke mRS score \>=2 * Uncontrolled hypertension * Previous treatment with erythropoietin * Previous exposure to Lu AA24493